What is HC Wainwright’s Estimate for PSTV FY2029 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Plus Therapeutics in a research note issued to investors on Friday, March 28th. HC Wainwright analyst S. Lee anticipates that the company will earn $0.95 per share for the year. HC Wainwright currently has a “Buy” rating and a $5.50 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.

A number of other equities research analysts have also commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Plus Therapeutics in a research report on Friday. Ascendiant Capital Markets cut their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.

Plus Therapeutics Stock Down 23.7 %

Shares of Plus Therapeutics stock opened at $1.16 on Monday. The stock has a market cap of $6.84 million, a price-to-earnings ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.67. The company’s fifty day moving average is $1.11 and its 200 day moving average is $1.24.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.